Diagnostic accuracy of FGFR2 gene alterations in endoscopic transpapillary biopsy specimens of hilar cholangiocarcinoma

Diagnostic accuracy of FGFR2 gene alterations in endoscopic transpapillary biopsy specimens of hilar cholangiocarcinoma - Diagnostic accuracy of FGFR2 gene alterations in endoscopic transpapillary biopsy specimens of hilar cholangiocarcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060141

Enrollment

100

Registered

2026-04-01

Start date

2026-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perihilar cholangiocarcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were diagnosed with cancer by preoperative bile duct biopsy and subsequently underwent surgery at Nagoya University Hospital between January 1, 2015, and July 31, 2025, and who were pathologically confirmed to have perihilar cholangiocarcinoma were included.

Exclusion criteria

Exclusion criteria: Patients who received preoperative chemotherapy.

Design outcomes

Primary

Measure	Time frame
We calculated the concordance rate of FGFR2 mutations between surgical specimens and biopsy specimens in patients with perihilar cholangiocarcinoma.	—

Countries

Japan

Contacts

Public ContactYoshihisa Takada

Nagoya Univercity Graduate school of medicine Department of Clinical Research Education

ytakada@med.nagoya-u.ac.jp0527442458

Outcome results